[11C]-MeJDTic: a novel radioligand for kappa-opioid receptor positron emission tomography imaging.

  title={[11C]-MeJDTic: a novel radioligand for kappa-opioid receptor positron emission tomography imaging.},
  author={G{\'e}raldine Poisnel and Farhana Oueslati and Martine Dhilly and J{\'e}r{\^o}me Delamare and C{\'e}cile Perrio and Dani{\`e}le Debruyne and Louisa Barr{\'e}},
  journal={Nuclear medicine and biology},
  volume={35 5},
INTRODUCTION Radiopharmaceuticals that can bind selectively the kappa-opioid receptor may present opportunities for staging clinical brain disorders and evaluating the efficiency of new therapies related to stroke, neurodegenerative diseases or opiate addiction. The N-methylated derivative of JDTic (named MeJDTic), which has been recently described as a potent and selective antagonist of kappa-opioid receptor in vitro, was labeled with carbon-11 and evaluated for in vivo imaging the kappa… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 11 extracted citations


Publications referenced by this paper.
Showing 1-10 of 40 references

Synthesis and biodistribution of [11C]R107474, a new radiolabeled a2-adrenoceptor antagonist

  • M Van der Mey, AD Windhorst, RP Klok, JDM Herscheid, LE Kennis, F Bischoff
  • Bioorg Med Chem
  • 2006
1 Excerpt

Opioids as potential treatments for stimulant dependence

  • TE Prinsinzano, K Tidgewell, WW. Harding
  • AAPS J 2005;7:E592–9
  • 2005
1 Excerpt

Similar Papers

Loading similar papers…